Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Receivables (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Receivables for 16 consecutive years, with $4000.0 as the latest value for Q4 2025.

  • Quarterly Receivables rose 33.33% to $4000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4000.0 through Dec 2025, up 33.33% year-over-year, with the annual reading at $4000.0 for FY2025, 33.33% up from the prior year.
  • Receivables hit $4000.0 in Q4 2025 for Guided Therapeutics, down from $6000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $256000.0 in Q1 2022 to a low of $2000.0 in Q2 2024.
  • Historically, Receivables has averaged $65113.1 across 5 years, with a median of $7721.0 in 2023.
  • Biggest five-year swings in Receivables: tumbled 96.11% in 2023 and later soared 300.0% in 2025.
  • Year by year, Receivables stood at $126000.0 in 2021, then rose by 3.96% to $130984.0 in 2022, then plummeted by 94.32% to $7442.0 in 2023, then plummeted by 59.69% to $3000.0 in 2024, then skyrocketed by 33.33% to $4000.0 in 2025.
  • Business Quant data shows Receivables for GTHP at $4000.0 in Q4 2025, $6000.0 in Q3 2025, and $8000.0 in Q2 2025.